XAF1 (XIAP-associated factor 1) is a tumor suppressor protein that interacts with X-linked inhibitor of apoptosis (XIAP), a key regulator of caspase activity and apoptosis. Discovered in 2000. XAF1 functions as a pro-apoptotic factor by counteracting XIAP's anti-apoptotic effects, promoting caspase activation and sensitizing cells to apoptotic stimuli. Its expression is often downregulated in various cancers due to epigenetic silencing (e.g., promoter hypermethylation) or genetic alterations, correlating with tumor progression, therapy resistance, and poor prognosis. XAF1 also exhibits antiviral properties by enhancing interferon signaling pathways.
XAF1 antibodies are essential tools for investigating its biological roles, including subcellular localization (nucleocytoplasmic shuttling), protein-protein interactions, and regulatory mechanisms in apoptosis and immune responses. Researchers utilize these antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess XAF1 expression patterns in normal tissues versus malignancies. In cancer research, XAF1 antibodies help evaluate its potential as a diagnostic/prognostic biomarker or therapeutic target, particularly in cancers like colorectal, gastric, and hepatocellular carcinomas where XAF1 dysregulation is prominent. Recent studies also explore its involvement in inflammatory diseases and viral infections, expanding its relevance beyond oncology.